Panbela Therapeutics, Inc. (PBLA)
USD 0.26
(-3.7%)
USD 0.26
(-3.7%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.61 Million USD | -52.94% |
| 2022 | 5.55 Million USD | 146.84% |
| 2021 | -11.86 Million USD | -31.53% |
| 2020 | -9.02 Million USD | -286.71% |
| 2019 | -2.33 Million USD | -121.14% |
| 2018 | -1.05 Million USD | -163.06% |
| 2017 | 1.67 Million USD | -41.07% |
| 2016 | 2.83 Million USD | 18.29% |
| 2015 | 2.4 Million USD | 481.12% |
| 2014 | 412.99 Thousand USD | -21.01% |
| 2013 | 522.87 Thousand USD | 9.99% |
| 2012 | 475.37 Thousand USD | -8.57% |
| 2011 | 519.92 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 3.93 Million USD | 50.31% |
| 2024 Q2 | 4.13 Million USD | 5.16% |
| 2023 Q4 | 2.61 Million USD | -38.98% |
| 2023 Q2 | -2.01 Million USD | -4804.88% |
| 2023 Q3 | 4.28 Million USD | 313.18% |
| 2023 FY | 2.61 Million USD | -52.94% |
| 2023 Q1 | -41 Thousand USD | -100.74% |
| 2022 FY | 5.55 Million USD | 146.84% |
| 2022 Q2 | 4.31 Million USD | 175.21% |
| 2022 Q3 | 5.9 Million USD | 36.83% |
| 2022 Q4 | 5.55 Million USD | -5.83% |
| 2022 Q1 | -5.73 Million USD | 51.66% |
| 2021 Q1 | -8.09 Million USD | 9.07% |
| 2021 FY | -11.86 Million USD | -31.53% |
| 2021 Q4 | -11.86 Million USD | 15.67% |
| 2021 Q3 | -14.07 Million USD | -119.7% |
| 2021 Q2 | -6.4 Million USD | 20.91% |
| 2020 Q1 | -463 Thousand USD | 80.15% |
| 2020 Q3 | -10.73 Million USD | -691.3% |
| 2020 Q2 | -1.35 Million USD | -192.87% |
| 2020 Q4 | -8.9 Million USD | 17.0% |
| 2020 FY | -9.02 Million USD | -286.71% |
| 2019 Q4 | -2.33 Million USD | 4.03% |
| 2019 Q1 | -37 Thousand USD | 96.49% |
| 2019 FY | -2.33 Million USD | -121.14% |
| 2019 Q2 | 253 Thousand USD | 783.78% |
| 2019 Q3 | -2.43 Million USD | -1060.87% |
| 2018 Q3 | 86 Thousand USD | 114.83% |
| 2018 Q4 | -1.05 Million USD | -1326.74% |
| 2018 FY | -1.05 Million USD | -163.06% |
| 2018 Q1 | 1.08 Million USD | -35.09% |
| 2018 Q2 | -580 Thousand USD | -153.41% |
| 2017 Q4 | 1.67 Million USD | 269.32% |
| 2017 Q2 | -229 Thousand USD | 88.0% |
| 2017 Q1 | -1.9 Million USD | -167.24% |
| 2017 FY | 1.67 Million USD | -41.07% |
| 2017 Q3 | 453 Thousand USD | 297.82% |
| 2016 Q1 | 2.87 Million USD | 19.71% |
| 2016 FY | 2.83 Million USD | 18.29% |
| 2016 Q2 | 1.36 Million USD | -52.49% |
| 2016 Q4 | 2.83 Million USD | 39.1% |
| 2016 Q3 | 2.04 Million USD | 49.52% |
| 2015 Q1 | 317.11 Thousand USD | -23.22% |
| 2015 FY | 2.4 Million USD | 481.12% |
| 2015 Q4 | 2.4 Million USD | 55.95% |
| 2015 Q3 | 1.53 Million USD | 213.8% |
| 2015 Q2 | 490.43 Thousand USD | 54.65% |
| 2014 Q4 | 412.99 Thousand USD | -7.66% |
| 2014 Q1 | 508.35 Thousand USD | -2.78% |
| 2014 Q3 | 447.25 Thousand USD | -1.63% |
| 2014 FY | 412.99 Thousand USD | -21.01% |
| 2014 Q2 | 454.67 Thousand USD | -10.56% |
| 2013 Q3 | 476.56 Thousand USD | -10.66% |
| 2013 Q4 | 522.87 Thousand USD | 9.72% |
| 2013 Q1 | 528.76 Thousand USD | 11.23% |
| 2013 FY | 522.87 Thousand USD | 9.99% |
| 2013 Q2 | 533.41 Thousand USD | 0.88% |
| 2012 FY | 475.37 Thousand USD | -8.57% |
| 2012 Q4 | 475.37 Thousand USD | 0.0% |
| 2011 FY | 519.92 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | -44.043% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 168.571% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -108.612% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 91.88% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 378.594% |
| Better Therapeutics, Inc. | -860 Thousand USD | 404.186% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 110.999% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -696.49% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 42.757% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 144.925% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 18.199% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 17.39% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 47.701% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 98.048% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -1360.229% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 78.798% |
| Molecular Templates, Inc. | 707 Thousand USD | -270.014% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -496.655% |
| NexImmune, Inc. | -3.13 Million USD | 183.481% |
| Orgenesis Inc. | 21.78 Million USD | 87.991% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 525401.205% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 155.534% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 2199.94% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 97.64% |
| Statera Biopharma, Inc. | 14.41 Million USD | 81.854% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 134.439% |
| Trevena, Inc. | 2.25 Million USD | -15.855% |
| Vaxxinity, Inc. | 10.13 Million USD | 74.181% |
| Vaccinex, Inc. | -1.28 Million USD | 303.106% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -659.48% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 80.24% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -3535.252% |